tiragolumab

The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up
Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up
Fierce Biotech
Roche
Tigit
clinical trials
lung cancer
non-small cell lung cancer
tiragolumab
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Flag link:
Roche keeps the faith in new cancer immunotherapy despite trial setbacks
Roche keeps the faith in new cancer immunotherapy despite trial setbacks
BioPharma Dive
Roche
tiragolumab
lung cancer
clinical trials
ASCO 2022
Flag link:
3 cancer drug studies to watch at next month’s ASCO meeting
3 cancer drug studies to watch at next month’s ASCO meeting
BioPharma Dive
ASCO 2022
AstraZeneca
Enhertu
Gilead Sciences
Trodelvy
Roche
tiragolumab
cancer
Flag link:
Roche believes cancer drug setback not a fatal blow to growth prospects
Roche believes cancer drug setback not a fatal blow to growth prospects
Reuters
Roche
drug development
tiragolumab
Flag link:
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling
Fierce Biotech
Roche
tiragolumab
anti-TIGIT
non-small cell lung cancer
clinical trials
Flag link:
Roche's closely watched immunotherapy fails key study in tough-to-treat lung cancer
Roche's closely watched immunotherapy fails key study in tough-to-treat lung cancer
BioPharma Dive
Roche
tiragolumab
clinical trials
Tigit
advanced small cell lung cancer
Flag link:
Big pharma’s key second-quarter data
Big pharma’s key second-quarter data
EP Vantage
Roche
tiragolumab
Giredestrant
Sanofi
Eli Lilly
tirzepatide
Novo Nordisk
GSK
Pfizer
RSV
Flag link:
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
Fierce Pharma
FDA
drug approvals
FibroGen
AstraZeneca
daprodustat
Bristol Myers Squibb
Opdivo
Roche
tiragolumab
Merck
favezelima
bInnovent
Eli Lilly
Akeso Biopharma
Sino Biopharmaceutical
Novartis
Ukoniq
TG Therapeutics
GW Pharmaceuticals
Marinus Pharmaceuticals
Flag link:
A year of TIGIT (and Alzheimer’s) for Roche
A year of TIGIT (and Alzheimer’s) for Roche
EP Vantage
Roche
Tigit
tiragolumab
Alzheimer's disease
Flag link:
Roche builds case for TIGIT combo in untreated lung cancer
Roche builds case for TIGIT combo in untreated lung cancer
Pharmaforum
Roche
anti-TIGIT
tiragolumab
Tecentriq
lung cancer
Flag link:
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq
Pharmaceutical Business Review
Roche
FDA
tiragolumab
Tecentriq
non-small cell lung cancer
breakthrough therapies
Flag link:
Roche’s TIGIT drug shows promise in untreated lung cancer
Roche’s TIGIT drug shows promise in untreated lung cancer
Pharmaforum
Roche
ASCO 2020
tiragolumab
Tecentriq
metastatic non-small cell lung cancer
Flag link:
ASCO 2020 – first-line lung cancer focus
ASCO 2020 – first-line lung cancer focus
EP Vantage
Roche
Merck
Bristol-Myers Squibb
ASCO 2020
lung cancer
Keytruda
tiragolumab
Opdivo
Yervoy
Flag link:
Roche move endorses Iteos’s Tigit widget
Roche move endorses Iteos’s Tigit widget
EP Vantage
Roche
Tigit
tiragolumab
Arcus Biosciences
iTeos Therapeutics
Flag link: